Dr. Reddy's Laboratories acquires Habitrol Brand from Novartis
M2 - Fri Dec 19, 7:09AM CST
Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) reported on Thursday the completion of the acquisition of title and rights of Habitrol brand from Novartis Consumer Health under an asset purchase agreement.
RDY: 49.58 (-0.10), NVS: 93.91 (+0.66)
Dr. Reddy's Laboratories Closes the Acquisition of Habitrol(R) Brand from Novartis
Business Wire - Fri Dec 19, 1:18AM CST
Dr. Reddy's Laboratories has announced that it has closed the acquisition of Habitrol(R) brand (an over-the-counter nicotine replacement therapy transdermal patch) from Novartis Consumer Health Inc. following issuance of the proposed consent order from the U.S. Federal Trade Commission (FTC) on November 26, 2014. The company had earlier entered into an asset purchase agreement with Novartis Consumer Health Inc. to acquire the title and rights of Habitrol(R) brand and to market the product in the U.S. market.
RDY: 49.58 (-0.10), NVS: 93.91 (+0.66)
Dr. Reddy's Laboratories (RDY) in Focus: Stock Falls 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 8:06AM CST
Dr. Reddy's Laboratories stock fell over 7% last trading session, continuing its recent downtrend
AKRX: 36.47 (+0.43), RDY: 49.58 (-0.10)
Stock Futures Point Lower; Russia, India Stocks Pressured
at Investor's Business Daily - Tue Dec 16, 8:20AM CST
Stock futures were moderately lower ahead of Tuesday's open, despite volatile overseas stock and currency trading. Dow futures were 29.8 points below fair market value and off their early lows. Nasdaq 100 futures were under some serious pressure,...
TLM: 7.84 (unch), RUSS: 24.00 (-2.60), RDY: 49.58 (-0.10), NUGT: 10.13 (+0.76), IBN: 11.65 (+0.08), JNUG: 20.87 (+2.01), HDB: 50.86 (-0.06), RSX: 15.95 (+0.51), YNDX: 17.66 (-0.32)
Dr. Reddy's launches generic version of Valcyte in U.S.
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 7:19AM CST
RDY: 49.58 (-0.10)
Dr. Reddy's unveils Valganciclovir Tablets, USP in the US
M2 - Tue Dec 16, 6:15AM CST
Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) reported on Tuesday the availability of Valganciclovir Tablets USP 450 mg in the US market on 15 December 2014.
RDY: 49.58 (-0.10)
Dr. Reddy's Announces the Launch of Valganciclovir Tablets, USP
Business Wire - Tue Dec 16, 1:57AM CST
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Valganciclovir Tablets USP 450 mg, a therapeutic equivalent generic version of VALCYTE(R) (Valganciclovir) tablets in the US market on December 15, 2014, approved by the United States Food & Drug Administration (USFDA).
RDY: 49.58 (-0.10)
Dr Reddys Laboratories Up 16.2% Since SmarTrend Uptrend Call (RDY)
Comtex SmarTrend(R) - Mon Dec 01, 11:21AM CST
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on October 23rd, 2014 at $50.46. In approximately 1 month, Dr Reddys Laboratories has returned 16.22% as of today's recent price of $58.64.
RDY: 49.58 (-0.10)
FTC gives thumbs up to Glaxo/Novartis transaction
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 2:48PM CST
RDY: 49.58 (-0.10), GSK: 42.85 (+0.11), NVS: 93.91 (+0.66)
Dr. Reddy's unveils Docetaxel Injection USP in the US market
M2 - Mon Nov 24, 7:16AM CST
Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) disclosed on Monday the availability of Docetaxel Injection USP 20 mg/ml and 80 mg/4 ml in a single dose and one vial formulation in the US market.
RDY: 49.58 (-0.10)
Dr. Reddy's Announces the Launch of Docetaxel Injection USP
Business Wire - Mon Nov 24, 1:29AM CST
Dr. Reddy's Laboratories (NYSE: RDY) announced today that is has launched Docetaxel Injection USP 20 mg/mL and 80 mg/4 mL a therapeutic equivalent generic version of TAXOTERE(R) (docetaxel Injection) in the US market on November 21, 2014. Dr. Reddy's ANDA is approved by the United States Food & Drug Administration (USFDA).
RDY: 49.58 (-0.10)
Dr. Reddy's unveils OTC Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg ERTablets in the US
M2 - Fri Nov 21, 5:30AM CST
Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) disclosed on Thursday the introduction of its US FDA approved over-the-counter (OTC) Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets 60 mg / 120 mg in a 20 count blister in the US market.
RDY: 49.58 (-0.10)
Dr. Reddy's Announces the Launch of Over-the-Counter Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets
Business Wire - Thu Nov 20, 8:15AM CST
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched its over-the-counter (OTC) Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets 60 mg / 120 mg, a bioequivalent generic version of Allegra-D(R) 12 Hour Allergy & Congestion, in the U.S. market on November 18, 2014. Dr. Reddy's ANDA is approved by the United States Food & Drug Administration (USFDA).
RDY: 49.58 (-0.10)
Sucampo-Takeda Sue Dr. Reddy's for Amitiza Patent Violation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 3:30PM CST
Sucampo Pharmaceuticals, Inc. (SCMP) and partner Takeda Pharmaceutical Company Limited filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Dr. Reddy's Laboratories (RDY).
JAZZ: 165.33 (+1.83), ARQL: 1.15 (+0.01), SCMP: 13.75 (+0.44), RDY: 49.58 (-0.10)
Dr. Reddy's cleared for generic Valcyte
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:34AM CST
ENDP: 72.10 (+0.34), RDY: 49.58 (-0.10)
Dr. Reddy's (RDY) Q2 Earnings Fall, Revenues Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 4:20PM CDT
Dr. Reddy's Laboratories (RDY) reported second-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 54 cents, down 17% from the year-ago quarter.
MNK: 97.84 (-0.29), ACT: 254.20 (-1.68), MYL: 56.97 (+0.39), RDY: 49.58 (-0.10)
Dr. Reddy's Laboratories (RDY) Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 12:50AM CDT
RDY: 49.58 (-0.10)
Dr. Reddys ups revenues 7% in FQ2
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 12:43PM CDT
RDY: 49.58 (-0.10)
Dr. Reddy's FQ2 EPS of $0.54
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 5:55AM CDT
RDY: 49.58 (-0.10)